Kentucky Governor Andy Beshear (D) recently rescinded a 2022 executive order that allowed medical cannabis patients to use and possess cannabis products outside the state, WLWT5 reports.

The governor initially issued the order to streamline qualifying patient access to medical cannabis products while the state worked to implement its program. Beshear said this week that with Kentucky’s medical cannabis program now fully operational, protections for patients who possess out-of-state products will end on July 1.

Meanwhile, the governor signed another executive order this month, adding 15 new qualifying medical conditions in the program. That order caused opposite reactions by several top Republicans, who called on officials to prosecute any medical cannabis licensees who comply with the governor’s latest order.

Also, an Office of Inspector General investigation into the state’s medical cannabis licensing process determined Earlier this year, Kentucky’s Office of Medical Cannabis (OMC) licensing methods were “transparent and fair” to all applicants.

The Kentucky Office of the Inspector General announced Thursday that it has concluded an investigation into the medical cannabis licensing process implemented by the state’s Office of Medical Cannabis (OMC).

“After an independent review of the program, the licensing process it established in the regulations, and related regulations and statutes, this office found that the OMC created an effective program that was fully transparent and fair to all license applicants.” – Excerpt from REPORT

The report comes a year after the OMC requested an investigation into the process.

Gov. Andy Beshear praised the program during a recent Kntucky Team Update, stating that “The Office of Medical Cannabis stated that the regulations and licensing processes were designed with two goals in mind—fairness and transparency—and the OIG report clearly acknowledged that those goals were met.” WHAS11 reports.

Meanwhile, Kentucky’s medical cannabis program began last December, serving registered patients diagnosed with conditions including cancer, chronic pain or nausea, epilepsy, multiple sclerosis or post-traumatic stress disorder (PTSD).